Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults ≥ 18 years of age capable of providing informed consent

• Pathologically confirmed diagnosis of PMF, post-ET MF, or post-PV MF as per the World Health Organization (WHO) diagnostic criteria - Intermediate-1, Intermediate-2, or High-Risk disease by the Dynamic International Prognostic Scoring System (DIPSS)

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Baseline splenomegaly ≥ 5cm palpable below the left costal margin and in the midclavicular line OR ≥ 450cc by imaging (i.e. ultrasound, CT, MRI)

• Baseline anemia, defined by hemoglobin \< 10 g/dL within 28 days prior to Cycle 1 Day 1

• Baseline thrombocytopenia, defined by platelet count 50-150 x 109/L without platelet transfusions within 28 days prior to Cycle 1 Day 1

• Adequate organ function as demonstrated by the following within 28 days prior to Cycle 1 Day 1:

‣ ALT (SGPT) and/or AST (SGOT) ≤ 3x the upper limit of normal (ULN), or ≤ 4 x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH);

⁃ Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH) or documented Gilbert's syndrome;

⁃ Creatinine clearance ≥ 30 mL/min;

⁃ Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (Exceptions to coagulation parameters may be considered for patients who are taking concomitant anticoagulation medications or have a documented anti-phospholipid antibody, after discussion with Study Chair approval)

⁃ Bone marrow and/or peripheral blood blast count \< 5%; and

⁃ Absolute neutrophil count (ANC) ≥ 1500 mm3 without need for growth factors within 7 days prior to Cycle 1 Day 1.

• Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia

• Life expectancy of at least six months

• Patients with active hepatitis B virus are eligible if antiviral therapy for hepatitis B has been given for \>8 weeks and the viral load is \<100 IU/mL.

• Patients with history of hepatitis C virus (HCV) are eligible if they have received adequate curative anti-HCV treatment and HCV viral load is below the limit of quantification.

• Patients with history of human immunodeficiency virus are eligible if they have cluster of differentiation (CD)4+ T-cell counts ≥350 cells/μL, negative viral load, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year and should be on established antiretroviral therapy for at least 4 weeks.

• Women of childbearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after the last dose of study therapy

• Able to adhere to the study visit schedule and all protocol requirements

Locations
United States
Kansas
The University of Kansas Cancer Center-Westwood
NOT_YET_RECRUITING
Westwood
North Carolina
Wake Forest Baptist Health Comprehensive Cancer Center
NOT_YET_RECRUITING
Winston-salem
New York
Icahn School of Medicine at Mount Sinai
RECRUITING
New York
Contact Information
Primary
Gillian Sanchez
gillian.sanchez@mssm.edu
(917) 581-1774
Backup
Shakira Forde
shakira.forde@mssm.edu
212-824-8334
Time Frame
Start Date: 2026-10-23
Estimated Completion Date: 2030-05-24
Participants
Target number of participants: 26
Treatments
Experimental: Pacritinib/Selinexor
Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen.
Sponsors
Collaborators: Sobi, Inc., Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Leads: John Mascarenhas

This content was sourced from clinicaltrials.gov

Similar Clinical Trials